Thalia Therapeutics
Thalia Therapeutics raises €3.1M and acquires Sanmirna Therapeutics, adding a clinical-stage microRNA candidate for AML.
Europe's most interesting startup stories. Every week.
No spam. Unsubscribe anytime.
Podcast Episode
🎙️ Deep Dive
Intu Diagnostics, Thalia Therapeutics, RarEarth — lab-free testing, clinical RNA and European rare earths — Daily News June 26, 2026
Listen to the episodeAbout Thalia Therapeutics
Thalia Therapeutics is a London-based biotech focused on RNA therapeutics and delivery technologies. In June 2026, it announced a €3.1M fundraise and the acquisition of Sanmirna Therapeutics, adding miRisten, a Phase 1 microRNA candidate for acute myeloid leukaemia, to its portfolio. The transaction accelerates Thalia's transition toward a clinical-stage pipeline.
The Story
Founded in 2014; in 2026 the company strengthened its RNA therapeutics strategy under CEO David Solomon and through the Sanmirna acquisition.
How Thalia Therapeutics works
Business Model
Clinical/preclinical biotech with potential monetisation through clinical development, licensing, pharma partnerships and future commercialisation.
Revenue Model
Not disclosed; expected biotech model based on licensing, partnerships, milestones and potential commercialisation.
Products & Services
Key Products
- miRisten
- RNA delivery technologies
- Nuvec platform
- Bispecific cardiovascular RNA assets
Core Use Cases
- Acute myeloid leukaemia
- RNA therapeutics
- Oncology
- Cardiovascular disease
Market & Clients
Key Customers
Future oncology and cardiovascular patients; currently clinical and preclinical development.
Geographic Presence
How Thalia Therapeutics competes
Competitors
Competitive Advantages
- Clinical-stage AML asset through Sanmirna
- RNA therapeutic focus
- Delivery technology platform
- Experienced biotech leadership
How Thalia Therapeutics grows
Growth Strategy
Complete miRisten Phase 1, advance cardiovascular assets toward IND and build a diversified RNA pipeline.
Distribution Model
Sviluppo biotech con potenziali partnership pharma e licensing.
Moat (Defensibility)
RNA pipeline, acquired clinical asset, delivery know-how and intellectual property.
Regulatory Context
Drug development subject to clinical trial regulation and approvals in relevant jurisdictions.
Key Risks
- Clinical risk
- Regulatory risk
- Integration risk after acquisition
- Funding needs for later-stage trials
Strategic Insights
- In biotech, M&A can change the risk profile and clinical maturity of a company.
- RNA pipelines remain strategically relevant in oncology and cardiovascular disease.
- A small fundraise can be strategic if linked to a clinical asset with readable milestones.
Funding & Investors
Funding Rounds
- 2026 - Fundraise: €3.1M / £2.75M
Key Investors
Founding Team
Key Executives
- Dr David H. Solomon - CEO
Key Metrics
Lessons from Thalia Therapeutics
- In biotech, stage progression matters as much as capital raised.
- A targeted acquisition can accelerate years of internal development.
- Milestone-based deal structures can reduce upfront risk while preserving upside.
Similar Startups
Ternary Therapeutics
Biotech company using synthetic biology to develop therapies for serious diseases with innovative treatment approaches.
Read AnalysisSTORM Therapeutics
Biotech company developing targeted therapies using proprietary cell-targeting technology.
Read AnalysisSources
- UK BioTech Thalia Therapeutics raises €3.1 million and acquires Sanmirna Therapeutics — BeBeez / EU-Startups
- Thalia Therapeutics Plc LinkedIn company profile — LinkedIn